Monograph Details
|
|
Musculoskeletal Disorders
> Bone disorders
|
|
BONIVA |
| Manufacturer |
|
Roche Laboratories |
| Legal Classification |
|
Rx
|
| Pharmacological Class |
|
Bisphosphonate. |
| Generic Name |
|
Ibandronate (as monosodium monohydrate) 2.5mg, 150mg; tabs. |
| Also |
|
• BONIVA INJECTION
|
| Indications |
|
Prevention and treatment of postmenopausal osteoporosis. |
| Children |
|
Not recommended. |
| Adults |
|
Swallow whole. Take in the AM with plain (not mineral) water (6–8oz), at least 60 minutes before the first food, drink, or medication of the day; do not lie down for at least 60 minutes after. 150mg once monthly (take on the same day each month), or 2.5mg once daily. Do not take two 150mg tablets within the same week. |
| Contraindications |
|
Uncorrected hypocalcemia. Severe renal impairment (CrCl<30mL/min or serum creatinine >2.3mg/dL): not recommended. Tabs: Inability to stand or sit upright for at least 60 minutes. |
| Precautions |
|
Discontinue if esophageal irritation occurs. Treat disturbances of mineral metabolism first. Ensure adequate Vit. D and calcium intake. Inj: check renal function before each dose (see Contraindications). Pregnancy (Cat.C). Nursing mothers. |
| Interactions |
|
May be antagonized by calcium, other multivalent cations (eg, magnesium, aluminum, iron, antacids); may interfere with absorption. Caution with aspirin, NSAIDs, other GI irritants. May interfere with bone-imaging agents. Concomitant nephrotoxic agents; monitor for renal toxicity. |
| Adverse Reactions |
|
GI upset, abdominal or musculoskeletal pain (may be severe), headache; dysphagia, esophagitis, esophageal or gastric ulcer, jaw osteonecrosis. Inj: inj site reactions, flu-like syndrome. |
| How Supplied |
Tabs 2.5mg—(available soon)
Tabs 150mg—3
Prefilled syringe (5mL)—1 (w. supplies) |
| Additional Resources |
|
• Related Prescribing Note |
|
|
|
|
